US EditionPublished • loading... • Updated
Wegovy is here, who will have access?
Summary by E-tangata.co.nz
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Wegovy is here, who will have access?
Wegovy is currently the only GLP-1 receptor agonist approved and available in New Zealand specifically for weight loss. Photo: (RNZ AFP / Jens Kalaene) Wegovy has arrived in New Zealand, three years after the US — and with it, the possibility of up-ending how we treat obesity, diabetes, and other chronic diseases. However, the early data tells a complicated story. While tens of thousands have started using Wegovy here, many of those who stand to…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
